• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Efficacy of Dupilumab for Controlling Severe Atopic Dermatitis in a Patient with Hyper-IgE Syndrome.度普利尤单抗治疗高IgE综合征患者严重特应性皮炎的疗效
J Clin Immunol. 2020 Feb;40(2):418-420. doi: 10.1007/s10875-020-00751-4. Epub 2020 Jan 28.
2
Patient with atopic dermatitis, hyper IgE syndrome and ulcerative colitis, treated successfully with dupilumab during pregnancy.患有特应性皮炎、高IgE综合征和溃疡性结肠炎的患者，在怀孕期间使用度普利尤单抗治疗成功。
Dermatol Ther. 2022 Feb;35(2):e15237. doi: 10.1111/dth.15237. Epub 2021 Dec 8.
3
Dupilumab to treat severe atopic dermatitis in autosomal dominant hyper-IgE syndrome.度普利尤单抗治疗常染色体显性高免疫球蛋白E综合征中的重度特应性皮炎。
Clin Immunol. 2020 Jun;215:108452. doi: 10.1016/j.clim.2020.108452. Epub 2020 Apr 29.
4
Efficacy and Safety of Nemolizumab for Treatment of Adult Atopic Dermatitis: A Meta-analysis of Randomized Clinical Trials.奈莫利珠单抗治疗成人特应性皮炎的疗效和安全性：一项随机临床试验的荟萃分析
J Investig Allergol Clin Immunol. 2021 Apr;31(2):190-192. doi: 10.18176/jiaci.0672.
5
Anti-IgE therapy and severe atopic dermatitis: a pediatric perspective.抗IgE疗法与重度特应性皮炎：儿科视角
J Am Acad Dermatol. 2013 Nov;69(5):832-834. doi: 10.1016/j.jaad.2013.05.035.
6
Atopic dermatitis or hyper-IgE syndrome?特应性皮炎还是高IgE综合征？
Allergy Asthma Proc. 2006 May-Jun;27(3):289-91. doi: 10.2500/aap.2006.27.2853.
7
Concurrent use of omalizumab and dupilumab in a 47-year-old woman with chronic spontaneous urticaria and atopic dermatitis.在一名患有慢性自发性荨麻疹和特应性皮炎的47岁女性中同时使用奥马珠单抗和度普利尤单抗。
Int J Dermatol. 2022 May;61(5):e173-e174. doi: 10.1111/ijd.16009. Epub 2021 Nov 23.
8
Treatment of severe atopic dermatitis and eosinophilic esophagitis with dupilumab in a 14-year-old boy with autosomal dominant hyper-IgE syndrome.度普利尤单抗治疗一名患有常染色体显性高IgE综合征的14岁男孩的重度特应性皮炎和嗜酸性食管炎。
J Allergy Clin Immunol Pract. 2021 Nov;9(11):4167-4169. doi: 10.1016/j.jaip.2021.06.049. Epub 2021 Jul 16.
9
Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?2017 年批准用于治疗特应性皮炎后dupilumab 的新进展：有哪些新进展和下一步计划？
Curr Opin Allergy Clin Immunol. 2019 Aug;19(4):341-349. doi: 10.1097/ACI.0000000000000551.
10
Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.度普利尤单抗在一大群难治性成人特应性皮炎患者中非常有效：来自 BioDay 登记处的首个临床和生物标志物结果。
Allergy. 2020 Jan;75(1):116-126. doi: 10.1111/all.14080. Epub 2019 Oct 31.

引用本文的文献

1
Pathological IgE Production in Inborn Errors of Immunity and Beyond.免疫先天性疾病及其他情况下的病理性IgE产生
Immunol Rev. 2025 Jul;332(1):e70053. doi: 10.1111/imr.70053.
2
Hyper IgE Syndrome: Bridging the Gap Between Immunodeficiency, Atopy, and Allergic Diseases.高免疫球蛋白E综合征：弥合免疫缺陷、特应性和过敏性疾病之间的差距。
Curr Allergy Asthma Rep. 2025 Mar 14;25(1):17. doi: 10.1007/s11882-025-01196-8.
3
The genetics of hyper IgE syndromes.高免疫球蛋白E综合征的遗传学
Front Immunol. 2025 Feb 18;16:1516068. doi: 10.3389/fimmu.2025.1516068. eCollection 2025.
4
Inborn errors of immunity with atopic phenotypes in the allergy and immunology clinic: a practical review.过敏与免疫门诊中具有特应性表型的先天性免疫缺陷：实用综述
Curr Opin Allergy Clin Immunol. 2025 Apr 1;25(2):105-114. doi: 10.1097/ACI.0000000000001059. Epub 2025 Feb 13.
5
Case report: Advanced age at transplantation and pre-emptive treatment with dupilumab in DOCK8 deficiency.病例报告：DOCK8缺陷患者移植时高龄及使用度普利尤单抗的抢先治疗
Front Immunol. 2025 Jan 28;15:1507494. doi: 10.3389/fimmu.2024.1507494. eCollection 2024.
6
Monogenic Inborn Errors of Immunity with impaired IgG response to polysaccharide antigens but normal IgG levels and normal IgG response to protein antigens.对多糖抗原的IgG反应受损但IgG水平正常且对蛋白质抗原的IgG反应正常的单基因遗传性免疫缺陷病。
Front Pediatr. 2024 Jun 12;12:1386959. doi: 10.3389/fped.2024.1386959. eCollection 2024.
7
Management of Atopy with Dupilumab and Omalizumab in CADINS Disease.CADINS 疾病中使用度普利尤单抗和奥马珠单抗治疗特应性的管理。
J Clin Immunol. 2024 Jan 17;44(2):48. doi: 10.1007/s10875-023-01636-y.
8
Hyper IgE syndrome-related disease treated with dupilumab: A case report.度普利尤单抗治疗高IgE综合征相关疾病：一例报告
Clin Case Rep. 2023 Sep 13;11(9):e7614. doi: 10.1002/ccr3.7614. eCollection 2023 Sep.
9
New Dominant-Negative IL6ST Variants Expand the Immunological and Clinical Spectrum of GP130-Dependent Hyper-IgE Syndrome.新型显性负性 IL6ST 变异扩展了依赖于 gp130 的高免疫球蛋白 E 综合征的免疫和临床谱。
J Clin Immunol. 2023 Oct;43(7):1566-1580. doi: 10.1007/s10875-023-01517-4. Epub 2023 Jun 5.
10
Dupilumab for Post-Hematopoietic Cell Transplantation Dermatitis in Wiskott-Aldrich Syndrome.度普利尤单抗用于治疗威斯科特-奥尔德里奇综合征造血干细胞移植后皮炎
J Clin Immunol. 2023 Oct;43(7):1526-1528. doi: 10.1007/s10875-023-01525-4. Epub 2023 May 29.

本文引用的文献

1
A recessive form of hyper-IgE syndrome by disruption of ZNF341-dependent STAT3 transcription and activity.一种由 ZNF341 依赖性 STAT3 转录和活性破坏引起的高 IgE 综合征的隐性形式。
Sci Immunol. 2018 Jun 15;3(24). doi: 10.1126/sciimmunol.aat4956.
2
ZNF341 controls STAT3 expression and thereby immunocompetence.ZNF341 控制 STAT3 的表达，从而调节免疫功能。
Sci Immunol. 2018 Jun 15;3(24). doi: 10.1126/sciimmunol.aat4941.
3
Primary atopic disorders.原发性过敏症。
J Exp Med. 2018 Apr 2;215(4):1009-1022. doi: 10.1084/jem.20172306. Epub 2018 Mar 16.
4
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.两项度普利尤单抗治疗特应性皮炎的 3 期临床试验。
N Engl J Med. 2016 Dec 15;375(24):2335-2348. doi: 10.1056/NEJMoa1610020. Epub 2016 Sep 30.
5
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.度普利尤单抗治疗中重度特应性皮炎成人患者。
N Engl J Med. 2014 Jul 10;371(2):130-9. doi: 10.1056/NEJMoa1314768.

Efficacy of Dupilumab for Controlling Severe Atopic Dermatitis in a Patient with Hyper-IgE Syndrome.

作者信息

Lévy Romain, Béziat Vivien, Barbieux Claire, Puel Anne, Bourrat Emmanuelle, Casanova Jean-Laurent, Hovnanian Alain

机构信息

Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, 75015, Paris, France.

Université de Paris, Imagine Institute, 75015, Paris, France.

出版信息

J Clin Immunol. 2020 Feb;40(2):418-420. doi: 10.1007/s10875-020-00751-4. Epub 2020 Jan 28.

DOI:10.1007/s10875-020-00751-4
PMID:31993867
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9642001/
Abstract
摘要